Skip to content
Preprint · OA via OpenAlex

Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression

Nour K. Majbour, Nishant N. Vaikath, Paolo Eusebi, Davide Chiasserini, Mustafa Taleb Ardah, Shiji Varghese, M. Emdadul Haque, Takahiko Tokuda, Peggy Auinger, Paolo Calabresi, Lucilla Parnetti, Omar M. A. El‐Agnaf

Movement Disorders · 2016 · ▲ 149 citations

Abstract

ABSTRACT Background Parkinson's disease (PD) diagnosis is mainly based on clinical criteria, with a high risk of misdiagnosis. The identification of reliable biomarkers for disease diagnosis and progression has a key role for developing disease‐modifying therapies. In this article, we investigated the longitudinal changes of CSF α‐synuclein species in early PD patients and explored the potential use of these species as surrogate biomarkers for PD progression. Methods We used our newly developed enzyme‐linked immunosorbent assay systems for measuring different forms of α‐synuclein, such as oligomeric‐α‐synuclein, phosphorylated‐α‐synuclein at serine 129, or total‐α‐synuclein in CSF from the longitudinal Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study cohort (n = 121). CSF Alzheimer's disease biomarkers (total‐tau, phosphorylated‐tau, Aβ40, and Aβ42) were also measured for this cohort. Results Interestingly, total‐α‐synuclein and oligomeric‐α‐synuclein levels significantly increased during the 2‐year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study follow‐up period, whereas phosphorylated‐α‐synuclein at serine 129 levels showed a longitudinal decrease. We have also noted an association between a change of the oligomeric‐α‐synuclein/total‐α‐synuclein ratio and a worsening of motor signs, in particular in the postural‐instability and gait‐difficulty dominant PD group. A strong positive correlation between the changes in CSF total‐α‐synuclein and oligomeric‐α‐synuclein during the 2‐year Deprenyl and Tocopherol Antioxidative Therapy for Parkinsonism study was also noted (r = 0.84, P < .001). Conclusion Our data show that CSF α‐synuclein species have a dynamic pattern along the course of the disease, supporting their possible role as progression biomarkers for PD and their link with PD clinical phenotypes. © 2016 International Parkinson and Movement Disorder Society

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1002/mds.26754
Canonical
link ↗
Fetched
2026-10-20 MST

Cite this

APA
Majbour, N.K., Vaikath, N.N., Eusebi, P., Chiasserini, D., Ardah, M.T., Varghese, S., Haque, M.E., Tokuda, T., Auinger, P., Calabresi, P., Parnetti, L., &amp; El‐Agnaf, O.M.A. (2016). Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression. <em>Movement Disorders</em>. https://doi.org/10.1002/mds.26754
Vancouver
Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah MT, Varghese S, et al. Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression. Movement Disorders. 2016. doi:10.1002/mds.26754.
BibTeX
@unpublished{nour2016Longit, title = {Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression}, author = {Nour K. Majbour and Nishant N. Vaikath and Paolo Eusebi and Davide Chiasserini and Mustafa Taleb Ardah and Shiji Varghese and M. Emdadul Haque and Takahiko Tokuda and Peggy Auinger and Paolo Calabresi and Lucilla Parnetti and Omar M. A. El‐Agnaf}, journal = {Movement Disorders}, year = {2016}, doi = {10.1002/mds.26754}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings